JP2015522616A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522616A5 JP2015522616A5 JP2015523160A JP2015523160A JP2015522616A5 JP 2015522616 A5 JP2015522616 A5 JP 2015522616A5 JP 2015523160 A JP2015523160 A JP 2015523160A JP 2015523160 A JP2015523160 A JP 2015523160A JP 2015522616 A5 JP2015522616 A5 JP 2015522616A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- item
- salt
- diffractogram
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940126062 Compound A Drugs 0.000 claims description 145
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 145
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 16
- 159000000000 sodium salts Chemical class 0.000 claims description 15
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 13
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 25
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 9
- 150000008545 L-lysines Chemical class 0.000 description 9
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 9
- 150000002169 ethanolamines Chemical class 0.000 description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 8
- -1 L-arginine salt Chemical class 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 2
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- NMFQPFSIPWZZMR-UHFFFAOYSA-N 1,1,1,2,3,3-hexafluoropropan-2-ol Chemical compound FC(F)C(F)(O)C(F)(F)F NMFQPFSIPWZZMR-UHFFFAOYSA-N 0.000 description 1
- 206010054936 Cardiac cirrhosis Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010022657 Intestinal infarction Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-Lysine Natural products NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- ULYBVEFKCOOSPY-UHFFFAOYSA-M potassium;2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetate Chemical compound [K+].C1=C2C(C)=NC(C(=O)NCC([O-])=O)=C(O)C2=CC=C1OC1=CC=CC=C1 ULYBVEFKCOOSPY-UHFFFAOYSA-M 0.000 description 1
- YOZBGTLTNGAVFU-UHFFFAOYSA-N roxadustat Chemical compound C1=C2C(C)=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C1OC1=CC=CC=C1 YOZBGTLTNGAVFU-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261672191P | 2012-07-16 | 2012-07-16 | |
| US61/672,191 | 2012-07-16 | ||
| US201361768297P | 2013-02-22 | 2013-02-22 | |
| US61/768,297 | 2013-02-22 | ||
| US201361832566P | 2013-06-07 | 2013-06-07 | |
| US61/832,566 | 2013-06-07 | ||
| PCT/US2013/050539 WO2014014835A2 (en) | 2012-07-16 | 2013-07-15 | Crystalline forms of a prolyl hydroxylase inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017203509A Division JP2018009034A (ja) | 2012-07-16 | 2017-10-20 | プロリルヒドロキシラーゼ阻害剤の結晶形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522616A JP2015522616A (ja) | 2015-08-06 |
| JP2015522616A5 true JP2015522616A5 (enExample) | 2016-09-01 |
| JP6491093B2 JP6491093B2 (ja) | 2019-03-27 |
Family
ID=48857025
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015523160A Active JP6491093B2 (ja) | 2012-07-16 | 2013-07-15 | プロリルヒドロキシラーゼ阻害剤の結晶形態 |
| JP2017203509A Pending JP2018009034A (ja) | 2012-07-16 | 2017-10-20 | プロリルヒドロキシラーゼ阻害剤の結晶形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017203509A Pending JP2018009034A (ja) | 2012-07-16 | 2017-10-20 | プロリルヒドロキシラーゼ阻害剤の結晶形態 |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US9115085B2 (enExample) |
| EP (3) | EP3470397B1 (enExample) |
| JP (2) | JP6491093B2 (enExample) |
| KR (4) | KR102149380B1 (enExample) |
| CN (9) | CN104684897A (enExample) |
| AU (1) | AU2013290438C1 (enExample) |
| BR (1) | BR112015001101A2 (enExample) |
| CA (1) | CA2879242C (enExample) |
| CY (2) | CY1120805T1 (enExample) |
| DK (2) | DK2872488T3 (enExample) |
| ES (2) | ES2689430T3 (enExample) |
| FR (1) | FR22C1030I2 (enExample) |
| HK (1) | HK1243409A1 (enExample) |
| HR (2) | HRP20181751T1 (enExample) |
| HU (2) | HUE057925T2 (enExample) |
| IL (1) | IL236626B (enExample) |
| IN (1) | IN2015KN00262A (enExample) |
| LT (3) | LT3470397T (enExample) |
| LU (1) | LUC00269I2 (enExample) |
| MX (1) | MX355428B (enExample) |
| MY (1) | MY182428A (enExample) |
| NO (1) | NO2022024I1 (enExample) |
| NZ (1) | NZ704662A (enExample) |
| PL (2) | PL3470397T3 (enExample) |
| PT (2) | PT2872488T (enExample) |
| RS (2) | RS63122B1 (enExample) |
| SG (3) | SG11201500236SA (enExample) |
| SI (2) | SI2872488T1 (enExample) |
| SM (2) | SMT201800565T1 (enExample) |
| WO (1) | WO2014014835A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103145616B (zh) | 2003-06-06 | 2015-09-30 | 菲布罗根有限公司 | 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途 |
| WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
| EP2670750B1 (en) | 2011-02-02 | 2016-09-14 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| EP3470397B1 (en) | 2012-07-16 | 2021-12-29 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| SG11201500234YA (en) | 2012-07-16 | 2015-02-27 | Fibrogen Inc | Process for making isoquinoline compounds |
| IL296484B2 (en) | 2013-06-06 | 2025-03-01 | Fibrogen Inc | Pharmaceutical formulations of HIF hydroxylase inhibitor |
| CN103694172A (zh) * | 2013-12-26 | 2014-04-02 | 辽宁亿灵科创生物医药科技有限公司 | 含氮杂芳基化合物的衍生物 |
| WO2016045125A1 (en) | 2014-09-28 | 2016-03-31 | Merck Sharp & Dohme Corp. | Inhibitors of hif prolyl hydroxylase |
| CN104892509B (zh) * | 2015-06-04 | 2018-03-09 | 苏州明锐医药科技有限公司 | 诺得司他的制备方法 |
| CN106916105A (zh) * | 2015-12-28 | 2017-07-04 | 徐州万邦金桥制药有限公司 | 一种纯化可博美的方法 |
| US11510917B2 (en) | 2016-02-19 | 2022-11-29 | Cornell University | HIF-stabilization and prevention of hyperoxia-induced neonatal lung disease |
| CN106187888A (zh) * | 2016-07-18 | 2016-12-07 | 江苏德源药业股份有限公司 | Fg‑4592单晶及其制备方法 |
| CN108017583B (zh) * | 2016-11-01 | 2021-04-06 | 徐州万邦金桥制药有限公司 | 一种可博美的制备方法 |
| CN107382986B (zh) * | 2017-08-02 | 2022-09-20 | 江苏艾立康医药科技有限公司 | 4-羟基-1-甲基异喹啉衍生物及其在增加内源性促红细胞生成素中的用途 |
| US11168057B2 (en) | 2017-08-11 | 2021-11-09 | Dr. Reddy's Laboratories Limited | Polymorphs and co-crystals of roxadustat |
| WO2019042485A1 (en) | 2017-08-30 | 2019-03-07 | Zentiva, K.S. | FORMS IN THE STRONG STATE OF ROXADUSTAT |
| ES2898878T3 (es) * | 2017-09-04 | 2022-03-09 | Sandoz Ag | Cocristal de un inhibidor de la prolil·hidroxilasa de HIF disponible por vía oral |
| CN110028431B (zh) | 2018-06-05 | 2021-01-08 | 沈阳化工大学 | 一种三氟乙基硫醚（亚砜）取代苯类化合物及其用途 |
| CN111320583A (zh) * | 2018-12-14 | 2020-06-23 | 广东东阳光药业有限公司 | 诺德司他新晶型及其制备方法 |
| CN109369525A (zh) * | 2018-12-29 | 2019-02-22 | 安礼特（上海）医药科技有限公司 | 罗沙司它的新晶型及其制备方法 |
| WO2020217190A1 (en) * | 2019-04-26 | 2020-10-29 | Dr. Reddy’S Laboratories Limited | Process for the purification of roxadustat |
| CN112679428A (zh) * | 2019-10-17 | 2021-04-20 | 罗欣药业(上海)有限公司 | 罗沙司他新晶型及其制备方法 |
| CN114344301B (zh) * | 2019-10-22 | 2023-06-23 | 苏州科睿思制药有限公司 | 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型 |
| CN110721185B (zh) * | 2019-11-13 | 2022-04-12 | 南京市儿童医院 | 罗沙司他用于心肌保护的用途 |
| CN112961107B (zh) * | 2019-12-13 | 2024-06-25 | 罗欣药业(上海)有限公司 | 罗沙司他的晶型及其制备方法 |
| EP4121009A4 (en) * | 2020-03-17 | 2024-04-17 | Zydus Lifesciences Limited | Formulation comprising hif prolyl hydroxylase inhibitors |
| WO2021216530A1 (en) | 2020-04-20 | 2021-10-28 | Akebia Therapeutics, Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| CN111205224B (zh) * | 2020-04-22 | 2020-08-25 | 南京佰麦生物技术有限公司 | 一种罗沙司他水合物的晶型及其制备方法和应用 |
| CN113754569B (zh) * | 2020-06-04 | 2024-07-02 | 四川国为制药有限公司 | 一种中间体化合物及其制备方法和用途 |
| CN111533691A (zh) * | 2020-06-08 | 2020-08-14 | 重庆三圣实业股份有限公司 | 一种罗沙司他的制备方法 |
| CN114057643B (zh) * | 2020-08-04 | 2023-02-28 | 成都苑东生物制药股份有限公司 | 一种罗沙司他共晶及其制备方法 |
| CN112194624A (zh) * | 2020-11-18 | 2021-01-08 | 江苏豪森药业集团有限公司 | 一种异喹啉类化合物的晶型及其制备方法 |
| CN112500344B (zh) * | 2020-11-18 | 2022-07-01 | 江苏豪森药业集团有限公司 | 罗沙司他晶型及其制备方法 |
| CN115724796A (zh) * | 2021-08-26 | 2023-03-03 | 成都苑东生物制药股份有限公司 | 一种罗沙司他新晶型及其制备方法 |
| CN113956200A (zh) * | 2021-12-16 | 2022-01-21 | 南京威凯尔生物医药科技有限公司 | 一种粒径控制的罗沙司他原料药的结晶工艺 |
| CN116410134A (zh) * | 2021-12-31 | 2023-07-11 | 北京济美堂医药研究有限公司 | 一种罗沙司他水合物晶体及其制备方法和应用 |
| WO2025111214A1 (en) | 2023-11-22 | 2025-05-30 | Fibrogen, Inc. | [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3- carbonyl)amino]acetic acid (roxadustat) for the treatment of anemia in subjects with myelodysplastic syndrome (mds) |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036964A (en) | 1973-10-11 | 1977-07-19 | Beecham Group Limited | Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis |
| US3989704A (en) | 1973-10-30 | 1976-11-02 | Sandoz, Inc. | 3-Substituted-4-aryl isoquinolines |
| DE2818423A1 (de) | 1978-04-27 | 1979-11-08 | Hoechst Ag | Neue isochinolinderivate und verfahren zu ihrer herstellung |
| DE3233424A1 (de) | 1982-09-09 | 1984-03-15 | Hoechst Ag, 6230 Frankfurt | Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
| US4558006A (en) | 1983-02-04 | 1985-12-10 | Kirin-Amgen, Inc. | A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin |
| US4559403A (en) | 1983-05-19 | 1985-12-17 | Hoffmann-La Roche Inc. | Substituted isoquinolines |
| US4584379A (en) | 1985-01-22 | 1986-04-22 | Merrell Dow Pharmaceuticals Inc. | Isoquinoline thromboxane synthetase inhibitors |
| US4667016A (en) | 1985-06-20 | 1987-05-19 | Kirin-Amgen, Inc. | Erythropoietin purification |
| US4822800A (en) | 1986-06-09 | 1989-04-18 | Ortho Pharmaceutical Corporation | Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties |
| US4966906A (en) | 1987-11-27 | 1990-10-30 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-isoquinolinecarboxamides |
| US4952588A (en) | 1987-11-27 | 1990-08-28 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides |
| EP0650961B1 (de) | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| ATE149485T1 (de) | 1993-11-02 | 1997-03-15 | Hoechst Ag | Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel |
| CA2138929A1 (en) | 1993-12-30 | 1995-07-01 | Klaus Weidmann | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
| AU4515696A (en) | 1994-12-12 | 1996-07-03 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| PT944619E (pt) | 1996-11-27 | 2007-01-31 | Bristol Myers Squibb Pharma Co | Novos antagonistas dos receptores da integrina |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| FR2779963A1 (fr) | 1998-06-22 | 1999-12-24 | Centre Nat Rech Scient | Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer |
| IT1302677B1 (it) | 1998-10-15 | 2000-09-29 | Zambon Spa | Derivati benzazinici inibitori della fosfodiesterasi 4 |
| WO2000064877A1 (en) | 1999-04-26 | 2000-11-02 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
| IT1315220B1 (it) * | 1999-12-13 | 2003-02-03 | Ipm Ind Plastica Monregalese | Telone di foglia pluristrato di materia plastica per pacciamature e/ocome barriera di contenimento di sostanze di trattamento in |
| IT1320162B1 (it) | 2000-02-09 | 2003-11-18 | Rotta Research Lab | Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico. |
| FI20002044A0 (fi) | 2000-09-15 | 2000-09-15 | Orion Yhtymae Oyj | Comt-entsyymiä estäviä naftaleenijohdannaisia |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| JP4590157B2 (ja) | 2001-03-21 | 2010-12-01 | アイシス イノヴェイション リミテッド | アッセイ、方法および手段 |
| CA2450625A1 (en) | 2001-06-13 | 2002-12-19 | Genesoft Pharmaceuticals, Inc. | Isoquinoline compounds having antiinfective activity |
| US6716866B2 (en) | 2001-06-13 | 2004-04-06 | Genesoft Pharmaceuticals, Inc. | Aryl-benzimidazole compounds having antiinfective activity |
| US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
| HU229475B1 (en) | 2001-12-06 | 2014-01-28 | Fibrogen | Methods of increasing endogenous erythropoietin (epo) |
| US8318703B2 (en) | 2001-12-06 | 2012-11-27 | Fibrogen, Inc. | Methods for improving kidney function |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US20060018959A1 (en) | 2002-12-16 | 2006-01-26 | Kissei Pharmaceutical Co. Ltd. | Solid drug for oral use |
| CN103145616B (zh) | 2003-06-06 | 2015-09-30 | 菲布罗根有限公司 | 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途 |
| WO2005007192A2 (en) | 2003-06-06 | 2005-01-27 | Fibrogen, Inc. | Cytoprotection through the use of hif hydroxylase inhibitors |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| EP1646611A1 (en) | 2003-07-15 | 2006-04-19 | Merck & Co., Inc. | Hydroxypyridine cgrp receptor antagonists |
| EP1658074B1 (en) | 2003-08-01 | 2012-11-07 | Fibrogen, Inc. | Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers |
| US7544699B2 (en) | 2003-08-08 | 2009-06-09 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| WO2005087237A1 (ja) | 2004-03-16 | 2005-09-22 | Asahi Kasei Pharma Corporation | ファスジル含有製剤及びその安定性を改善する方法 |
| AU2005250412B2 (en) | 2004-05-28 | 2009-09-17 | Fibrogen, Inc. | HIF prolyl hydroxylase activity assay |
| GB2421013B (en) | 2004-12-10 | 2007-07-11 | Amcor Flexibles Europe As | Packaging with an openable top wall |
| US8703795B2 (en) | 2005-03-02 | 2014-04-22 | Fibrogen, Inc. | Thienopyridine compounds, and methods of use thereof |
| CN101849943A (zh) | 2005-06-06 | 2010-10-06 | 菲布罗根公司 | 使用HIFα稳定剂的改进的贫血治疗 |
| AU2006259352A1 (en) | 2005-06-15 | 2006-12-28 | Fibrogen, Inc. | Use of HIF 1alfa modulators for treatment of cancer |
| UA97349C2 (uk) | 2005-09-08 | 2012-02-10 | Х. Луннбэк А/С | Стійкі тверді склади сертиндолу |
| CN102351791B (zh) | 2006-01-27 | 2014-10-29 | 菲布罗根有限公司 | 使低氧诱导因子(hif)稳定的氰基异喹啉化合物 |
| US20070259960A1 (en) | 2006-02-16 | 2007-11-08 | Fibrogen, Inc. | Compounds and methods for treatment of stroke |
| AU2007234408B2 (en) | 2006-04-04 | 2011-05-19 | Fibrogen, Inc. | Pyrrolo- and thiazolo-pyridine compounds as HIF modulators |
| US20100172984A1 (en) | 2006-06-06 | 2010-07-08 | Bijay Kumar Padhi | tablet dosage form comprising cetirizine and pseudoephedrine |
| US7713986B2 (en) | 2006-06-15 | 2010-05-11 | Fibrogen, Inc. | Compounds and methods for treatment of chemotherapy-induced anemia |
| US20070293575A1 (en) | 2006-06-15 | 2007-12-20 | Fibrogen, Inc. | Compounds and methods for treatment of cancer-related anemia |
| JP5683058B2 (ja) | 2007-04-27 | 2015-03-11 | ニプロ株式会社 | 経口固形製剤及びその製造方法 |
| KR20100099113A (ko) | 2007-10-12 | 2010-09-10 | 아스트라제네카 아베 | 만니톨 및/또는 미세결정질 셀룰로스를 포함하는 지보텐탄 조성물 |
| WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
| US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
| US8324405B2 (en) | 2008-02-05 | 2012-12-04 | Fibrogen, Inc. | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors |
| CN102264740B (zh) | 2008-08-20 | 2014-10-15 | 菲布罗根有限公司 | 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途 |
| WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
| JP5479949B2 (ja) | 2009-04-08 | 2014-04-23 | 株式会社東芝 | 測定装置、測定方法、及び二酸化炭素回収システム |
| JP2010248106A (ja) | 2009-04-14 | 2010-11-04 | Dainippon Sumitomo Pharma Co Ltd | フィルムコーティング錠 |
| JP2012176899A (ja) | 2009-05-19 | 2012-09-13 | Mitsubishi Tanabe Pharma Corp | ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液 |
| US8339523B2 (en) | 2010-05-18 | 2012-12-25 | Kabushiki Kaisha Toshiba | Television apparatus and electronic apparatus |
| CN101880914B (zh) | 2010-05-25 | 2012-09-12 | 中国科学院微电子研究所 | 利用等离子体浸没离子注入制备黑硅的方法 |
| CN103429239A (zh) | 2011-01-13 | 2013-12-04 | 菲布罗根有限公司 | 增加网织红细胞血红蛋白含量的方法 |
| EP2670750B1 (en) | 2011-02-02 | 2016-09-14 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor |
| CA2842730C (en) * | 2011-07-22 | 2018-08-21 | Beijing Betta Pharmaceuticals Co., Ltd | Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
| US20140309256A1 (en) | 2011-11-09 | 2014-10-16 | Fibrogen, Inc. | Therapeutic Method |
| WO2013134660A1 (en) | 2012-03-09 | 2013-09-12 | Fibrogen, Inc. | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
| SG11201500234YA (en) * | 2012-07-16 | 2015-02-27 | Fibrogen Inc | Process for making isoquinoline compounds |
| EP3470397B1 (en) * | 2012-07-16 | 2021-12-29 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| SG10202009266PA (en) | 2013-01-24 | 2020-10-29 | Fibrogen Inc | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid |
| IL296484B2 (en) | 2013-06-06 | 2025-03-01 | Fibrogen Inc | Pharmaceutical formulations of HIF hydroxylase inhibitor |
-
2013
- 2013-07-15 EP EP18189607.7A patent/EP3470397B1/en active Active
- 2013-07-15 DK DK13740185.7T patent/DK2872488T3/en active
- 2013-07-15 PT PT13740185T patent/PT2872488T/pt unknown
- 2013-07-15 EP EP21212372.3A patent/EP4029854A1/en active Pending
- 2013-07-15 KR KR1020157003613A patent/KR102149380B1/ko active Active
- 2013-07-15 CN CN201380037479.XA patent/CN104684897A/zh active Pending
- 2013-07-15 SM SM20180565T patent/SMT201800565T1/it unknown
- 2013-07-15 HR HRP20181751TT patent/HRP20181751T1/hr unknown
- 2013-07-15 KR KR1020227041256A patent/KR20220164068A/ko not_active Ceased
- 2013-07-15 KR KR1020217034322A patent/KR20210130849A/ko not_active Ceased
- 2013-07-15 SG SG11201500236SA patent/SG11201500236SA/en unknown
- 2013-07-15 LT LTEP18189607.7T patent/LT3470397T/lt unknown
- 2013-07-15 HR HRP20220182TT patent/HRP20220182T1/hr unknown
- 2013-07-15 CN CN201710546619.6A patent/CN107382860A/zh active Pending
- 2013-07-15 ES ES13740185.7T patent/ES2689430T3/es active Active
- 2013-07-15 CA CA2879242A patent/CA2879242C/en active Active
- 2013-07-15 CN CN201810750543.3A patent/CN109369524A/zh active Pending
- 2013-07-15 HU HUE18189607A patent/HUE057925T2/hu unknown
- 2013-07-15 EP EP13740185.7A patent/EP2872488B1/en not_active Revoked
- 2013-07-15 US US13/942,443 patent/US9115085B2/en active Active
- 2013-07-15 CN CN201310302481.7A patent/CN103539735B/zh not_active Ceased
- 2013-07-15 PL PL18189607T patent/PL3470397T3/pl unknown
- 2013-07-15 JP JP2015523160A patent/JP6491093B2/ja active Active
- 2013-07-15 MX MX2015000504A patent/MX355428B/es active IP Right Grant
- 2013-07-15 CN CN201710546354.XA patent/CN107382859B/zh not_active Ceased
- 2013-07-15 KR KR1020207024326A patent/KR102318720B1/ko active Active
- 2013-07-15 SG SG10201700873UA patent/SG10201700873UA/en unknown
- 2013-07-15 CN CN202111361393.5A patent/CN114409596A/zh active Pending
- 2013-07-15 RS RS20220121A patent/RS63122B1/sr unknown
- 2013-07-15 CN CN201710546643.XA patent/CN107540607A/zh active Pending
- 2013-07-15 NZ NZ704662A patent/NZ704662A/en unknown
- 2013-07-15 PT PT181896077T patent/PT3470397T/pt unknown
- 2013-07-15 RS RS20181268A patent/RS57795B1/sr unknown
- 2013-07-15 MY MYPI2015000129A patent/MY182428A/en unknown
- 2013-07-15 DK DK18189607.7T patent/DK3470397T3/da active
- 2013-07-15 SG SG10202111314YA patent/SG10202111314YA/en unknown
- 2013-07-15 IN IN262KON2015 patent/IN2015KN00262A/en unknown
- 2013-07-15 SM SM20220095T patent/SMT202200095T1/it unknown
- 2013-07-15 WO PCT/US2013/050539 patent/WO2014014835A2/en not_active Ceased
- 2013-07-15 AU AU2013290438A patent/AU2013290438C1/en active Active
- 2013-07-15 SI SI201331143T patent/SI2872488T1/sl unknown
- 2013-07-15 LT LTEP13740185.7T patent/LT2872488T/lt unknown
- 2013-07-15 BR BR112015001101A patent/BR112015001101A2/pt not_active Application Discontinuation
- 2013-07-15 CN CN202210791828.8A patent/CN115093370A/zh active Pending
- 2013-07-15 ES ES18189607T patent/ES2905898T3/es active Active
- 2013-07-15 CN CN201710546191.5A patent/CN107501177B/zh not_active Ceased
- 2013-07-15 HU HUE13740185A patent/HUE041458T2/hu unknown
- 2013-07-15 SI SI201331973T patent/SI3470397T1/sl unknown
- 2013-07-15 PL PL13740185T patent/PL2872488T3/pl unknown
-
2015
- 2015-01-11 IL IL236626A patent/IL236626B/en active IP Right Grant
- 2015-07-21 US US14/805,345 patent/US9617218B2/en active Active
-
2017
- 2017-03-17 US US15/462,688 patent/US10118897B2/en active Active
- 2017-10-20 JP JP2017203509A patent/JP2018009034A/ja active Pending
-
2018
- 2018-02-28 HK HK18102870.1A patent/HK1243409A1/zh unknown
- 2018-10-11 US US16/158,242 patent/US20190276408A1/en not_active Abandoned
- 2018-10-31 CY CY181101128T patent/CY1120805T1/el unknown
-
2019
- 2019-12-16 US US16/716,433 patent/US20200115344A1/en not_active Abandoned
-
2022
- 2022-02-14 CY CY20221100127T patent/CY1125155T1/el unknown
- 2022-06-15 FR FR22C1030C patent/FR22C1030I2/fr active Active
- 2022-06-15 NO NO2022024C patent/NO2022024I1/no unknown
- 2022-06-15 LU LU00269C patent/LUC00269I2/en unknown
- 2022-06-20 LT LTPA2022510C patent/LTC3470397I2/lt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102435676B1 (ko) | 독성 알데히드 관련된 질병 및 치료 | |
| JP2017537940A5 (enExample) | ||
| JP2024516371A5 (enExample) | ||
| RU2012150108A (ru) | Аналоги глюкагоноподобного пептида-1 и их применение | |
| JP2012508752A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| JP2020519654A5 (enExample) | ||
| JP2021532108A (ja) | ビス第四級アンモニウム化合物及びその製造方法と使用 | |
| WO2009082818A8 (en) | Novel c-21-keto lupane derivatives preparation and use thereof | |
| JP2017512186A5 (enExample) | ||
| JP2021523887A (ja) | ＸＩＩａ因子インヒビター | |
| JP2017525699A5 (enExample) | ||
| JP2017533964A5 (enExample) | ||
| JP2015508068A5 (enExample) | ||
| JP2014513123A5 (enExample) | ||
| RU2015134420A (ru) | Кристаллические формы { [1-циано-5-(4-хлорофеноксид)-4-гидроксид-изохинолин-3-карбонил]-амино} -уксусной кислоты | |
| JP2017522304A5 (enExample) | ||
| KR101168136B9 (ko) | 혈압 강하용 약제학적 조성물 | |
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| JP2025508071A5 (enExample) | ||
| KR20100029097A (ko) | 안트라닐아미드 피리딘우레아와 벤즈아미드 유도체의 상승작용적 조합물 | |
| MX2024014315A (es) | Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas | |
| RU2013120549A (ru) | Новые кристаллические формы натриевой соли(4-{4-[5-(6-трифторметил-пиридин-3-иламино) пиридин-2-ил] фенил} циклогексил) уксусной кислоты | |
| RU2485102C2 (ru) | Циклические индол-3-карбоксамиды, их получение и их применение в качестве лекарственных препаратов | |
| JP2013516475A5 (enExample) |